(Q41587132)

4 October 2017

1 reference

title

Recombinant viruses as vaccines and immunological tools (English)

1 reference

4 October 2017

1 reference

Rolph MS

1

1 reference

PubMed ID

9287173

4 October 2017

Ramshaw IA

series ordinal

2

1 reference

4 October 2017

1 August 1997

1 reference

Current Opinion in Immunology

4 October 2017

1 reference

4 October 2017

9

1 reference

4 October 2017

517-524

1 reference

4 October 2017

4

1 reference

The new vaccines: building viruses that elicit antitumor immunity.

4 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Viral vectors in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Efficacy studies on a canarypox-rabies recombinant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Adenovirus vectors as recombinant viral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Human adenovirus type 5 vectors expressing rabies glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Engineering poliovirus as a vaccine vector for the expression of diverse antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBj14.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

The Th1-Th2 hypothesis of HIV infection: new insights

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

The role of interleukin-6 in mucosal IgA antibody responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

CD40 ligand has potent antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Alphavirus-based expression vectors: strategies and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

Negative-strand RNA viruses: genetic engineering and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980104-5

7 January 2021

10.1016/S0952-7915(97)80104-5

Identifiers

DOI

1 reference

4 October 2017

1 reference

PubMed ID

9287173